Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

Abstract: A method of separating actinium and/or radium from proton-irradiated thorium metal. The thorium metal is irradiated to produce isotopes including thorium, actinium and/or radium. The resultant product is dissolved in solution and a selective precipitant is used to precipitate a bulk portion of the thorium. The precipitated thorium can be recovered. Chromatography is carried out on the remaining solution to remove residual thorium and to separate the actinium from the radium.

Abstract: A capacitance sensor 1A in which first electrodes 3(1) to 3(4) and a second electrode 4 are arranged on a base material 2 made of a dielectric includes grounded electrostatic shielding members (5(1) to 5(6)). The electrostatic shielding members 5 are arranged, for example, at positions between first wiring portions 6(1)in, 6(2)in, 6(4) in connected to the first electrodes 3(1), 3(2), 3(4) and the second electrode 4, at a position between a second wiring portion 6(5)in connected to the second electrode 4 and the first electrode 3(4), and at a position between the second wiring portion 6(5)in and the first wiring portion 6(4)in.

Abstract: A metal alloy is provided which includes by weight percentage of the metal alloy, 28 to 55 percent copper, 45 to 63 percent nickel, and 4 to 10 percent iron. The metal alloy may be weight percentage 28 percent copper, 62 percent nickel, and 10 percent iron. The metal alloy may be formed into a foil which may have a thickness of 100 ?m or less or 50 ?m or less. A magnetic field instrument may include a magnetometer core body formed from one or more layers of the foil. The magnetometer core body may be a ring core or a racetrack core. The magnetic field instrument may further include a sense winding and may further include a drive winding. The magnetic field instrument may be a fluxgate magnetometer.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: An apparatus for facilitating electromagnetic wave resonator tuning is disclosed, including first, second, and third spaced apart resonator portions, the second portion disposed between the first and third to form an electromagnetic wave resonator having a resonant frequency, wherein the first and second portions define a first volume therebetween and the second and third define a second volume therebetween, a first actuator coupled to the first portion, the second, or both, the first actuator configured to adjust a width of the first volume, and a second actuator coupled to the second portion, the third, or both, the second actuator configured to adjust a width of the second volume, wherein the actuators are configured to decrease the widths of the first and second volumes or increase the widths of the first and second volumes to adjust the resonant frequency of the resonator. Other apparatuses, methods, and systems are also disclosed.

Abstract: The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

Abstract: The present invention provides vaccines against respiratory viruses including coronavirus, such as SARS-CoV-2, and influenza viruses. In particular, the present invention provides vaccines against SARS-CoV-2 which encode a targeting domain and a SARS-CoV-2 spike protein or fragment thereof.

Abstract: Apparatuses and methods for producing hydrogen peroxide by performing coupled chemical and electrochemical reactions are disclosed. An electrochemical cell has a chemical reaction chamber configured to hydrogenate a shuttle molecule and an electrochemical chamber configured to electrochemically dissociate water to form hydrogen ions at an anode, and to reduce the hydrogen ions to atomic hydrogen at a cathode. The chemical reaction chamber and the anode chamber are separated by a metallic membrane. The metallic membrane acts as a cathode of the cell, a hydrogen-selective layer and a catalyst. The metallic membrane may comprise a layer of palladium or a palladium alloy. A layer of co-catalyst may optionally be electrodeposited on the layer of palladium or palladium alloy. An ion exchange membrane separates the metallic membrane and the anode chamber. The hydrogenated shuttle molecule may be supplied to a reactor for contacting an oxygen-containing gas to yield hydrogen peroxide.

Abstract: Methods predict candidate epitopes in a protein by: providing a conformational sampling engine; obtaining a model of a protein suitable for use with the conformational sampling engine and comprising a native structure; applying a collective coordinate bias to the protein model, the collective coordinate bias causing the conformational sampling engine to in turn force the protein model to at least partially unfold from its native structure to an updated structure, wherein the collective coordinate bias is applied globally to at least a substantial portion of the protein model and is impartial as to where, within the substantial portion of the protein model, unfolding occurs; and analyzing the updated structure to identify one or more candidate epitopes, where the one or more candidate epitopes exhibit indicia of localized unfolding.

Abstract: Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of a-humulene and/or ?-caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an Enterococcus faecium or an Enterococcus faecalis. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.

Abstract: A triaxial force sensor 1 includes nine first electrodes 11 to 19, and nine second electrodes 21 to 29 attached to an electrode support 10 in such a manner that the electrode support 10 is interposed between the nine first electrodes 11 to 19 and the nine second electrodes 21 to 29. A pair of first electrodes 14 and 16 are arranged such that a straight line connecting the two is orthogonal to a straight line connecting a pair of first electrodes 12 and 18, and the second electrodes 22, 24, 26, and 28 are arranged such that the respective halves overlap the first electrodes 12, 14, 16, and 18 in plan view. The sensor has a number of components and size, thereby allowing a reduction in manufacturing cost, in the case of detecting forces in orthogonal triaxial directions.

Abstract: In an electrostatic capacity sensor 1, first electrodes 11a to 11d are provided on a substrate 10, and an electrode support 14 has dielectric properties and elasticity and is fixed to the substrate 10. A second electrode 12 is provided in the electrode support 14 so as to face the first electrodes 11a to 11d with a distance from the first electrodes 11a to 11d. The electrostatic capacity sensor has improved durability.

Abstract: Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

Abstract: Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.

Abstract: Methods for using compositions comprising a Granzyme B inhibitor and a pharmaceutically acceptable carrier for treating and/or preventing blistering and/or peeling of a skin of a subject are provided. Also provided are methods for using the compositions to improve the healing of a blistered or area of peeled skin of a subject. The compositions can be formulated for oral administration, nasal administration, topical administration, subcorneal administration, intra-epidermal administration, sub-epidermal administration, or for administration by injection.

Abstract: Apparatuses and methods for performing coupled chemical and electrochemical reactions are disclosed. An electrochemical cell has a first reaction chamber configured to perform a chemical reaction and an anode chamber configured to perform an electrochemical reaction. The first reaction chamber and the anode chamber are separated by a first membrane. The first membrane acts as a cathode of the cell, a hydrogen-selective layer and a catalyst. The first membrane may comprise a layer of palladium or a palladium alloy. An ion exchange membrane separates the first membrane and the anode chamber. The chemical and electrochemical reactions may respectively be hydrogenation and dehydrogenation reactions.

Abstract: Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

Abstract: A UV reactor irradiates a flow of fluid with UV radiation. The reactor comprises: a fluid conduit defined by a heat conducting conduit body comprising one or more heat conducting walls for permitting a flow of fluid therethrough; a UV-LED operatively connected to a PCB and oriented for directing radiation into the fluid conduit. The PCB comprises a heat conducting substrate having a first surface. The conduit body is in thermal contact with the first surface of the heat conducting substrate. Heat is dissipated from the UV-LED via the heat conducting substrate, the thermal contact between the first surface of the heat conducting substrate and the heat conducting conduit body, and from the one or more heat conducting walls of the heat conducting conduit body to the fluid flowing through the fluid conduit.

Abstract: Provided herein are antiviral compounds having the structure of Formula (I) and compositions thereof for use in the treatment of viral infection. In particular, the compounds of Formula (I) are capable of interfering with the export of viral mRNA processing as reflected in the altered accumulation of viral RNA isoforms as well as transport from the nucleus to the cytoplasm. Such compounds show a reduction of HIV, adenovirus and coronavirus infection of cells. The invention provides compounds that may be suitable for the treatment of HIV/AIDS.